Interleukin-4 Improves Metabolic Abnormalities in Leptin-Deficient and High-Fat Diet Mice.
IL-4
adiposity
inflammation
leptin
obesity
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Jun 2020
23 Jun 2020
Historique:
received:
02
06
2020
revised:
18
06
2020
accepted:
22
06
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
23
3
2021
Statut:
epublish
Résumé
Obesity is a metabolic disorder that results from complex interactions between genetic predisposition and dietary factors. Interleukin-4 (IL-4), besides its role in immunity, has metabolic effects on insulin efficacy. We studied the effects of IL-4 on metabolic abnormalities in a mice model of obesity involving leptin deficiency and leptin resistance. Leptin-deficient 145E and leptin-resistant high-fat diet (HFD) mice showed lower levels of circulating IL-4. 145E and HFD mice showed a number of abnormalities: Obesity, hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, liver injury, and adiposity with concurrent inflammation, decreases in Akt, signal transducer and activator of transcription 3 (STAT3), and STAT6 phosphorylation in the hypothalamus, liver, and epididymal fat. Independent of leptin-deficient obesity and dietary obesity, a course of 8-week IL-4 supplementation improved obesity and impairment in Akt, STAT3, and STAT6 signaling. Amelioration of cytokine expression, despite variable extents, was closely linked with the actions of IL-4. Additionally, the browning of white adipocytes by IL-4 was found in epididymal white adipose tissues and 3T3-L1 preadipocytes. Chronic exercise, weight management, and probiotics are recommended to overweight patients and IL-4 signaling is associated with clinical improvement. Thus, IL-4 could be a metabolic regulator and antiobesity candidate for the treatment of obesity and its complications.
Identifiants
pubmed: 32585823
pii: ijms21124451
doi: 10.3390/ijms21124451
pmc: PMC7352748
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Leptin
0
Interleukin-4
207137-56-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Taichung Veterans General Hospital
ID : TCVGH-1088202C
Organisme : Veterans General Hospitals and University System of Taiwan Joint Research Program
ID : VGHUST104-G7-8-2
Organisme : Veterans General Hospitals and University System of Taiwan Joint Research Program
ID : VGHUST105-G7-8-2
Références
Am J Physiol Endocrinol Metab. 2010 Jul;299(1):E47-53
pubmed: 20371733
Clin Sci (Lond). 2019 Jul 22;133(14):1603-1607
pubmed: 31331992
J Biol Chem. 2012 Apr 20;287(17):13561-71
pubmed: 22396530
Metabolism. 2016 Nov;65(11):1614-1620
pubmed: 27733249
J Biomed Res. 2017 Sep 03;:
pubmed: 28866659
Endocrinol Diabetes Metab. 2019 Feb 08;2(2):e00045
pubmed: 31008360
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Oncotarget. 2017 Jun 28;8(38):63417-63429
pubmed: 28969001
Clin Exp Immunol. 2007 Jun;148(3):583-8
pubmed: 17403060
Metabolism. 2010 Dec;59(12):1717-22
pubmed: 20580039
J Immunol. 2007 Jun 1;178(11):6886-93
pubmed: 17513737
Cytokine. 2012 Aug;59(2):309-12
pubmed: 22633285
Nat Commun. 2018 Nov 19;9(1):4863
pubmed: 30451856
Am J Physiol. 1997 May;272(5 Pt 2):R1365-70
pubmed: 9176325
Cardiovasc Diabetol. 2019 Mar 19;18(1):36
pubmed: 30890169
Int J Obes (Lond). 2018 Feb;42(2):252-259
pubmed: 28925407
Am J Physiol Endocrinol Metab. 2000 Oct;279(4):E838-45
pubmed: 11001766
Sci Rep. 2017 May 26;7(1):2447
pubmed: 28550279
J Nutr Biochem. 2020 Apr;78:108335
pubmed: 31978713
Mol Metab. 2018 Feb;8:1-12
pubmed: 29289646
J Clin Invest. 2020 Apr 1;130(4):2001-2016
pubmed: 32149734
Sci Rep. 2016 Jul 05;6:28508
pubmed: 27378381
Cells. 2019 Apr 24;8(4):
pubmed: 31022919
PLoS One. 2010 Dec 09;5(12):e15333
pubmed: 21151569
JAMA. 2018 Sep 18;320(11):1172-1191
pubmed: 30326501
Expert Opin Ther Targets. 2015 Jul;19(7):893-909
pubmed: 25726860
Eur J Intern Med. 2018 Feb;48:6-17
pubmed: 29100895
Int J Obes (Lond). 2017 Jan;41(1):129-136
pubmed: 27677620
Molecules. 2019 Dec 19;25(1):
pubmed: 31861678
Curr Diab Rep. 2014 Aug;14(8):508
pubmed: 24919749
Oxid Med Cell Longev. 2018 Nov 21;2018:6923187
pubmed: 30584465
Brain Res. 1999 Dec 18;851(1-2):198-203
pubmed: 10642844
Obesity (Silver Spring). 2013 Nov;21(11):2310-21
pubmed: 23418126
Diabetologia. 2018 Mar;61(3):526-538
pubmed: 29143855
Curr Diabetes Rev. 2014 Mar;10(2):131-45
pubmed: 24809394
Science. 2011 Apr 8;332(6026):243-7
pubmed: 21436399
Nature. 1997 Jun 26;387(6636):903-8
pubmed: 9202122
Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22617-22
pubmed: 21149710
Sci Rep. 2019 Aug 19;9(1):11974
pubmed: 31427606
Sci Rep. 2016 Jan 18;6:19288
pubmed: 26775807
J Neuroendocrinol. 2019 Jul;31(7):e12763
pubmed: 31251830
Cytokine. 2017 Oct;98:51-58
pubmed: 27916613
J Immunol. 2017 Apr 1;198(7):2927-2934
pubmed: 28193830
Obes Rev. 2015 Mar;16(3):207-24
pubmed: 25589226
Biomed Pharmacother. 2018 Mar;99:375-383
pubmed: 29358130
J Clin Invest. 2013 Jan;123(1):261-71
pubmed: 23257358
J Lipid Res. 2014 Mar;55(3):385-97
pubmed: 24347527
Int J Obes (Lond). 2012 Jul;36(7):993-8
pubmed: 21894160
Biochemistry (Mosc). 2018 May;83(5):498-506
pubmed: 29738684
Mediators Inflamm. 2019 Nov 11;2019:4182015
pubmed: 31814802
Biochem Biophys Res Commun. 2020 May 7;525(3):662-667
pubmed: 32127173
Gene Ther. 2008 Apr;15(7):504-15
pubmed: 18239607
Physiol Behav. 2010 Jan 12;99(1):33-9
pubmed: 19835896